Do analysts prefer RYM or NERV?

Minerva Neurosciences has a consensus price target of $10.33, indicating a potential upside of 310.05%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Minerva Neurosciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer RYM or CRDL?

Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 733.33%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer RYM or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, RYM or MENS?

Jyong Biotech has lower revenue, but higher earnings than RYTHM. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 2.40 -$33.26M -$10.53 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is RYM or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Jyong Biotech's return on equity of 0.00% beat RYTHM's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Jyong Biotech N/A N/A N/A

Do analysts recommend SBTX or RYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend RYM or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, RYM or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than RYTHM. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 2.40 -$33.26M -$10.53 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

RYTHM (RYM) Competitors

$18.41 -0.32 (-1.71%)

As of 01:27 PM Eastern

Compare

RYM vs. NERV, CRDL, MENS, SBTX, and RFAI

Should you buy RYTHM stock or one of its competitors? RYTHM's main competitors and comparable companies include Minerva Neurosciences (NERV), Cardiol Therapeutics (CRDL), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), and RF Acquisition Corp II (RFAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RYTHM compare to Minerva Neurosciences?

RYTHM (NASDAQ:RYM) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

RYTHM has higher revenue and earnings than Minerva Neurosciences. RYTHM is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

RYTHM has a beta of 9.46, suggesting that its share price is 846% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

6.0% of RYTHM shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Minerva Neurosciences had 1 more articles in the media than RYTHM. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for RYTHM. RYTHM's average media sentiment score of 1.79 beat Minerva Neurosciences' score of 0.89 indicating that RYTHM is being referred to more favorably in the media.

Company	Overall Sentiment
RYTHM	Very Positive
Minerva Neurosciences	Positive

Minerva Neurosciences has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Minerva Neurosciences' return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Minerva Neurosciences	N/A	N/A	-31.72%

Minerva Neurosciences has a consensus price target of $10.33, indicating a potential upside of 310.05%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Minerva Neurosciences	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

RYTHM and Minerva Neurosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does RYTHM compare to Cardiol Therapeutics?

RYTHM (NASDAQ:RYM) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 733.33%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, RYTHM and RYTHM both had 1 articles in the media. RYTHM's average media sentiment score of 1.79 equaled Cardiol Therapeutics'average media sentiment score.

Company	Overall Sentiment
RYTHM	Very Positive
Cardiol Therapeutics	Very Positive

Cardiol Therapeutics has lower revenue, but higher earnings than RYTHM. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

RYTHM has a beta of 9.46, meaning that its share price is 846% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

6.0% of RYTHM shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cardiol Therapeutics beats RYTHM on 8 of the 12 factors compared between the two stocks.

How does RYTHM compare to Jyong Biotech?

RYTHM (NASDAQ:RYM) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Jyong Biotech's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Jyong Biotech	N/A	N/A	N/A

Jyong Biotech has lower revenue, but higher earnings than RYTHM.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

RYTHM has a beta of 9.46, meaning that its share price is 846% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

In the previous week, RYTHM and RYTHM both had 1 articles in the media. Jyong Biotech's average media sentiment score of 1.82 beat RYTHM's score of 1.79 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
RYTHM	Very Positive
Jyong Biotech	Very Positive

6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Jyong Biotech beats RYTHM on 5 of the 9 factors compared between the two stocks.

How does RYTHM compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Silverback Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
RYTHM	-6.20%	-12.57%	-2.60%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 3.5% of RYTHM shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, RYTHM had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for RYTHM and 0 mentions for Silverback Therapeutics. RYTHM's average media sentiment score of 1.79 beat Silverback Therapeutics' score of 0.00 indicating that RYTHM is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
RYTHM	Very Positive

RYTHM has higher revenue and earnings than Silverback Therapeutics. RYTHM is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, RYTHM has a beta of 9.46, indicating that its stock price is 846% more volatile than the broader market.

Summary

RYTHM beats Silverback Therapeutics on 8 of the 12 factors compared between the two stocks.

How does RYTHM compare to RF Acquisition Corp II?

RYTHM (NASDAQ:RYM) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

RF Acquisition Corp II has lower revenue, but higher earnings than RYTHM.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.40	-$33.26M	-$10.53	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

RYTHM has a beta of 9.46, meaning that its share price is 846% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, RF Acquisition Corp II had 4 more articles in the media than RYTHM. MarketBeat recorded 5 mentions for RF Acquisition Corp II and 1 mentions for RYTHM. RYTHM's average media sentiment score of 1.79 beat RF Acquisition Corp II's score of 0.51 indicating that RYTHM is being referred to more favorably in the media.

Company	Overall Sentiment
RYTHM	Very Positive
RF Acquisition Corp II	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RF Acquisition Corp II has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RF Acquisition Corp II's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RF Acquisition Corp II	N/A	N/A	N/A

Summary

RF Acquisition Corp II beats RYTHM on 6 of the 10 factors compared between the two stocks.

Get RYTHM News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYM vs. The Competition

Export

Metric	RYTHM	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$40.13M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-1.75	807.81	275.40	25.37
Price / Sales	2.32	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	3.04	9.21	10.55	5.95
Net Income	-$33.26M	$2.84B	$3.50B	$380.75M
7 Day Performance	-5.10%	-4.00%	-3.92%	-3.96%
1 Month Performance	-16.24%	-8.07%	-8.30%	-6.81%
1 Year Performance	-59.79%	-5.86%	2.35%	-4.58%

RYTHM Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYM RYTHM	0.8264 of 5 stars	$18.41 -1.7%	N/A	-58.2%	$40.13M	$17.28M	N/A	141	Positive News Gap Up
NERV Minerva Neurosciences	1.7031 of 5 stars	$3.43 +3.3%	$10.33 +201.3%	-0.4%	$158.52M	N/A	N/A	7	News Coverage
CRDL Cardiol Therapeutics	3.4202 of 5 stars	$1.31 -0.8%	$10.00 +663.4%	+14.3%	$156.99M	N/A	N/A	18	Positive News High Trading Volume
MENS Jyong Biotech	N/A	$2.02 -1.5%	N/A	-96.3%	$155.86M	N/A	N/A	27	News Coverage Positive News
SBTX Silverback Therapeutics	N/A	$4.29 +5.4%	N/A	-63.1%	$154.69M	N/A	N/A	83	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RYTHM (RYM) Competitors

RYM vs. NERV, CRDL, MENS, SBTX, and RFAI

How does RYTHM compare to Minerva Neurosciences?

Summary

How does RYTHM compare to Cardiol Therapeutics?

Summary

How does RYTHM compare to Jyong Biotech?

Summary

How does RYTHM compare to Silverback Therapeutics?

Summary

How does RYTHM compare to RF Acquisition Corp II?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RYTHM (RYM) Competitors

RYM vs. NERV, CRDL, MENS, SBTX, and RFAI

How does RYTHM compare to Minerva Neurosciences?

Which has higher valuation & earnings, RYM or NERV?

Which has more risk & volatility, RYM or NERV?

Do insiders and institutionals believe in RYM or NERV?

Does the media prefer RYM or NERV?

Is RYM or NERV more profitable?

Do analysts prefer RYM or NERV?

Summary

How does RYTHM compare to Cardiol Therapeutics?

Do analysts prefer RYM or CRDL?

Does the media refer more to RYM or CRDL?

Which has better valuation and earnings, RYM or CRDL?

Which has more volatility & risk, RYM or CRDL?

Is RYM or CRDL more profitable?

Do institutionals & insiders have more ownership in RYM or CRDL?

Summary

How does RYTHM compare to Jyong Biotech?

Do analysts prefer RYM or MENS?

Is RYM or MENS more profitable?

Which has higher earnings & valuation, RYM or MENS?

Which has more volatility and risk, RYM or MENS?

Does the media refer more to RYM or MENS?

Do institutionals and insiders have more ownership in RYM or MENS?

Summary

How does RYTHM compare to Silverback Therapeutics?

Is SBTX or RYM more profitable?

Do insiders and institutionals hold more shares of SBTX or RYM?

Do analysts recommend SBTX or RYM?

Does the media refer more to SBTX or RYM?

Which has higher earnings & valuation, SBTX or RYM?

Which has more volatility & risk, SBTX or RYM?

Summary

How does RYTHM compare to RF Acquisition Corp II?

Which has stronger earnings and valuation, RYM or RFAI?

Which has more risk and volatility, RYM or RFAI?

Does the media prefer RYM or RFAI?

Do analysts recommend RYM or RFAI?

Do institutionals & insiders believe in RYM or RFAI?

Is RYM or RFAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools